PCVX Vaxcyte Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PCVX

Price (delayed)

$51.33

Market cap

$4.82B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.35

Enterprise value

$4.3B

Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious ...

Highlights
PCVX's quick ratio has surged by 84% year-on-year and by 37% since the previous quarter
Vaxcyte's equity has surged by 52% QoQ
The EPS has decreased by 32% YoY but it has increased by 2.9% from the previous quarter
The net income has plunged by 86% YoY and by 8% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://vaxcyte.com/
Peers: OMGA

Key stats

What are the main financial stats of PCVX
Market
Shares outstanding
93.85M
Market cap
$4.82B
Enterprise value
$4.3B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.36
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$264.77M
EBITDA
-$255.37M
Free cash flow
-$219.66M
Per share
EPS
-$3.35
Free cash flow per share
-$2.24
Book value per share
$15.3
Revenue per share
$0
TBVPS
$15.33
Balance sheet
Total assets
$1.5B
Total liabilities
$69.44M
Debt
$15.21M
Equity
$1.43B
Working capital
$1.25B
Liquidity
Debt to equity
0.01
Current ratio
21.76
Quick ratio
21.37
Net debt/EBITDA
2.02
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-27%
Return on equity
-28.7%
Return on invested capital
-59.5%
Return on capital employed
-18.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PCVX stock price

How has the Vaxcyte stock price performed over time
Intraday
-0.47%
1 week
1.95%
1 month
2.07%
1 year
110.2%
YTD
7.05%
QTD
2.78%

Financial performance

How have Vaxcyte's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$303.49M
Net income
-$264.77M
Gross margin
N/A
Net margin
N/A
Vaxcyte's operating income has shrunk by 111% YoY and by 15% QoQ
The net income has plunged by 86% YoY and by 8% from the previous quarter

Growth

What is Vaxcyte's growth rate over time

Valuation

What is Vaxcyte stock price valuation
P/E
N/A
P/B
3.36
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 32% YoY but it has increased by 2.9% from the previous quarter
Vaxcyte's equity has surged by 52% QoQ
The P/B is 6% lower than the last 4 quarters average of 3.6

Efficiency

How efficient is Vaxcyte business performance
PCVX's ROIC is up by 38% since the previous quarter and by 17% year-on-year
Vaxcyte's return on equity has increased by 34% YoY and by 23% QoQ
PCVX's ROA is up by 29% YoY and by 22% QoQ

Dividends

What is PCVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCVX.

Financial health

How did Vaxcyte financials performed over time
PCVX's quick ratio has surged by 84% year-on-year and by 37% since the previous quarter
Vaxcyte's current ratio has surged by 82% YoY and by 37% QoQ
The debt is 99% smaller than the equity
The company's debt to equity has shrunk by 83% YoY and by 50% QoQ
Vaxcyte's equity has surged by 52% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.